C-Bridge Capital, a China private equity firm with a life science focus, closed its second fund, C-Bridge Healthcare Fund II, at its $400 million cap. C-Bridge plans to invest in late-stage companies in the fields of biotechnology, pharmaceuticals, medical devices and health care, particularly those with cross-border ambitions. C-Bridge is active in Asia-Pacific – especially China – the US and Israel. Its first healthcare fund closed in 2014 after raising $200 million.
China Med Device, LLC, specializing in providing turn-key solutions for medtech companies’ entry into China, brings you up-to-date information on medical industry trends in China and related regions. If you have any feedback or inquiry regarding any of our services from China market assessment, CFDA registration, to funding and growth and product commercialization in China, please email us at info@ChinaMedDevice.com or visit us at www.ChinaMedDevice.com.